1. Combinatorial immunotherapy induces tumor-infiltrating CD8 + T cells with distinct functional, migratory, and stem-like properties.
- Author
-
Van Braeckel-Budimir N, Dolina JS, Wei J, Wang X, Chen SH, Santiago P, Tu G, Micci L, Al-Khami AA, Pfister S, Ram S, Sundar P, Thomas G, Long H, Yang W, Potluri S, and Salek-Ardakani S
- Subjects
- Animals, Cell Movement, Colorectal Neoplasms immunology, Colorectal Neoplasms metabolism, Colorectal Neoplasms pathology, Female, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Melanoma, Experimental immunology, Melanoma, Experimental metabolism, Melanoma, Experimental pathology, Mice, Mice, Inbred C57BL, Neoplastic Stem Cells pathology, Receptors, CXCR3 genetics, Single-Cell Analysis, CD8-Positive T-Lymphocytes immunology, Colorectal Neoplasms therapy, Immunotherapy methods, Lymphocytes, Tumor-Infiltrating immunology, Melanoma, Experimental therapy, Neoplastic Stem Cells immunology, Receptors, CXCR3 metabolism
- Abstract
Background: Programmed death (ligand) 1 (PD-(L)1) blockade and OX40/4-1BB costimulation have been separately evaluated in the clinic to elicit potent antitumor T cell responses. The precise mechanisms underlying single agent activity are incompletely understood. It also remains unclear if combining individual therapies leads to synergism, elicits novel immune mechanisms, or invokes additive effects., Methods: We performed high-dimensional flow cytometry and single-cell RNA sequencing-based immunoprofiling of murine tumor-infiltrating lymphocytes (TILs) isolated from hosts bearing B16 or MC38 syngeneic tumors. This baseline infiltrate was compared to TILs after treatment with either anti-PD-(L)1, anti-OX40, or anti-4-1BB as single agents or as double and triple combinatorial therapies. Fingolimod treatment and CXCR3 blockade were used to evaluate the contribution of intratumoral versus peripheral CD8
+ T cells to therapeutic efficacy., Results: We identified CD8+ T cell subtypes with distinct functional and migratory signatures highly predictive of tumor rejection upon treatment with single agent versus combination therapies. Rather than reinvigorating terminally exhausted CD8+ T cells, OX40/4-1BB agonism expanded a stem-like PD-1lo KLRG-1+ Ki-67+ CD8+ T cell subpopulation, which PD-(L)1 blockade alone did not. However, PD-(L)1 blockade synergized with OX40/4-1BB costimulation by dramatically enhancing stem-like TIL presence via a CXCR3-dependent mechanism., Conclusions: Our findings provide new mechanistic insights into the interplay between components of combinatorial immunotherapy, where agonism of select costimulatory pathways seeds a pool of stem-like CD8+ T cells more responsive to immune checkpoint blockade (ICB)., Competing Interests: Competing interests: Authors are present and former Pfizer employees and may hold stock/stock options in the company. Pfizer plans to file a patent application related to this work., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)- Published
- 2021
- Full Text
- View/download PDF